Moderna, Merck Vaccine Succeeds in Preventing Melanoma from Returning
marc__1
19 points
3 comments
August 19, 2026
Related Discussions
Found 5 related stories in 49.6ms across 4,128 title embeddings via pgvector HNSW
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial cwwc · 29 pts · August 19, 2026 · 80% similar
- Moderna, Merck cancer vaccine shows promise in late-stage phase three trial dominikposmyk · 19 pts · August 19, 2026 · 75% similar
- Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma heydenberk · 542 pts · August 19, 2026 · 64% similar
- New HIV vaccine shows unprecedented success in preclinical study codebyaditya · 610 pts · July 28, 2026 · 54% similar
- Frog bacterium wiped out cancer tumors in mice with a single dose dcyfr · 14 pts · July 11, 2026 · 43% similar
Discussion Highlights (3 comments)
cebert
Gift link: https://www.wsj.com/health/pharma/moderna-merck-vaccine-succ...
rvz
The news here is significant and this took decades of studies and research to validate this. Well done to Merck and Moderna.
root-parent
There is nothing to see here yet other than their stock popped 50%. Based on unpublished data... - The initial 49% number comes from a very small phase 2 trial that had only 157 patients. And their original p-value was 0.053 - This phase 3 news so far is nothing more than a press release. They have not published hazard ratio, or confidence interval, their event counts or survival curves. - They met the endppoint as used in the press release means nothing, until they publish the actual 3 data, so my money is at the end this will be a kind of marginal effect that researchers will struggle to reproduce for years This is the type of study that will take 3 to 4 years to validate or dismiss, in the meanwhile stock is up 50%....